Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback